

## Lucentis® (ranibizumab) Injection

When requesting Lucentis® (ranibizumab), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved compendial use and meet the specific coverage guidelines for the covered indication.

### FDA-Approved Indications

Lucentis is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic Retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)

### Approved Off-Label Compendial Uses

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, choroidal neovascular conditions)

### Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Lucentis is administered by or under the supervision of an ophthalmologist

**Approval duration: 12 months**

### Dosing Recommendations

#### **Neovascular (Wet) Age-Related Macular Degeneration (AMD)/Macular Edema Following Retinal Vein Occlusion (RVO)**

The recommended dose is 0.5 mg administered by intravitreal injection once a month.

#### **Diabetic Macular Edema (DME)/Diabetic Retinopathy (DR)**

The recommended dose is 0.3mg administered by intravitreal injection once a month.

#### **Myopic Choroidal Neovascularization (mCNV)**

The recommended dose is 0.5 mg administered by intravitreal injection once a month for up to 3 months.

## References

1. Lucentis® intravitreal injection [prescribing information]. South San Francisco, CA: Genentech, Inc.; March 2018.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.